<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990730</url>
  </required_header>
  <id_info>
    <org_study_id>H11397-34652-01</org_study_id>
    <secondary_id>F32HL097461-01</secondary_id>
    <secondary_id>SFGH GCRC 6128</secondary_id>
    <nct_id>NCT00990730</nct_id>
  </id_info>
  <brief_title>Atherosclerosis in Rheumatoid Arthritis</brief_title>
  <official_title>Atherosclerosis in Rheumatoid Arthritis: Role of Inflammation, Lipoproteins, and Endothelial Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the link between rheumatoid arthritis and&#xD;
      cardiovascular disease by studying inflammation, joint disease, cholesterol abnormalities,&#xD;
      and endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the general population, individuals with elevated inflammatory markers (e.g. C-reactive&#xD;
      protein, CRP) have increased cardiovascular disease. Patients with RA have chronic elevations&#xD;
      in CRP and other inflammatory markers that are usually higher than the levels associated with&#xD;
      increased cardiovascular risk in the general population. Indeed, RA patients have accelerated&#xD;
      disease of their blood vessels, and increased cardiovascular death not explained by&#xD;
      traditional cardiac risk factors but associated with chronic inflammation. However, the&#xD;
      mechanisms by which inflammation leads to cardiovascular disease are not well characterized&#xD;
      in RA. Moreover, current treatment strategies of RA largely target joint symptoms rather than&#xD;
      inflammation, potentially leaving patients at increased risk for cardiovascular disease.&#xD;
      Studies of markers that increase the risk of heart disease in the full spectrum of RA are&#xD;
      missing. We hypothesize that inflammatory markers will be more strongly associated with&#xD;
      abnormalities in blood vessels in RA patients than any clinical measure of disease activity.&#xD;
      This hypothesis will be tested with a cross-sectional study of patients in the UCSF RA&#xD;
      cohort. Aim 1 will characterize abnormal blood vessel changes across the spectrum of RA&#xD;
      disease activity, specifically measuring ultrasound of the upper arm artery, markers of&#xD;
      oxidative stress, and abnormalities in cholesterol proteins. Aim 2 will identify factors&#xD;
      associated with these changes across the spectrum of RA disease activity, specifically&#xD;
      focusing on the association between inflammatory markers, cholesterol, and blood vessel&#xD;
      abnormalities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>flow mediated vasodilation of the brachial artery, measured by ultrasound</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity/arterial stiffness</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid metabolism</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse ampitude</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>rheumatoid arthritis subjects</arm_group_label>
    <description>60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>20 matched controls without rheumatoid arthritis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RA subjects are from the UCSF RA cohort based at San Francisco General Hospital and UCSF&#xD;
        Medical Center. Controls will be selected from primary care clinics from these hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of RA by ACR criteria&#xD;
&#xD;
          -  Age 18-80&#xD;
&#xD;
          -  Enrolled in UCSF RA cohort already&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes (on meds or in medical history)&#xD;
&#xD;
          -  Pregnant or Lactating&#xD;
&#xD;
          -  Renal failure (Creatinine &gt; 2mg/dL or on dialysis)&#xD;
&#xD;
          -  History of MI or CAD&#xD;
&#xD;
          -  History of ischemic CVA&#xD;
&#xD;
          -  Symptomatic PVD&#xD;
&#xD;
          -  Current uncontrolled hypertension (blood pressure &gt; 160/100mmHg)&#xD;
&#xD;
          -  Daily prednisone &gt; 10mg daily&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  New BP med within 3 months&#xD;
&#xD;
          -  New statin within 3 months&#xD;
&#xD;
          -  Change in RA meds: new or increase in prednisone within 1 month, new TNF inhibitor&#xD;
             within 2 months, titration of methotrexate, leflunomide or sulfasalazine within 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscilla Y Hsue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Ganz, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF San Francisco General Hospital Vascular Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>January 23, 2012</last_update_submitted>
  <last_update_submitted_qc>January 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Priscilla Hsue</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>lipoproteins</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>arterial stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

